Functional polymers as human therapeutic agents

Industrial and Engineering Chemistry Research

Volumn 44, Issue 23, 2005, Pages 8593-8604

  Dhal, Pradeep K ^a   Huval, Chad C ^a   Holmes Farley, S Randall ^a  

^a GENZYME CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL ANEMIA; HUMAN THERAPEUTIC AGENTS;

DRUG PRODUCTS; MOLECULAR WEIGHT; TOXIC MATERIALS;

FUNCTIONAL POLYMERS;

MEDICAL APPLICATION; POLYMER;

EID: 28444482030     PISSN: 08885885     EISSN: None     Source Type: Journal    
DOI: 10.1021/ie040290i     Document Type: Review

References (102)

1. Jagur-Grodzinki, J. Biomedical applications of functional polymers. React. Funct. Polym. 1999, 39, 99.
2. Langer, R.; Tirrell, D. A. Designing materials for biology and medicine. Nature 2004, 428, 487.
3. Ringsdorf, H. Structure and properties of pharmacologically active polymers. J. Polym. Sci., Polym. Symp. 1975, 51, 135.
4. Luo, Y.; Prestwish, G. D. Cancer targeted polymeric drugs. Curr. Cancer Drug Targets 2002, 2, 209.
5. Ulbrich, K.; Pechar, M.; Strohalm, J.; Subr, V. Polymeric carriers of drugs for site- specific therapy. Macromol. Symp. 1997, 118, 577.
6. Takakura, Y.; Hashida, M. Macromolecular carrier systems for targeted drug delivery. Pharm. Res. 1996, 13, 820.
7. Harris, J. M.; Chess, R. B. Effect of pegylation on pharmaceuticals, Nat. Rev. Drug Discov. 2003, 2, 214.
8. Garnett, M. C. Gene-delivery systems using cationic polymers. Crit. Rev. Ther. Drug Carrier Syst. 1999, 16, 147.
9. Gros, L.; Ringsdorf, H.; Schupp, H. Polymeric antitumor agents on a molecular and on a cellular level. Angew. Chem., Int. Ed. Engl. 1981, 20, 305.
10. Langer, R. Drug delivery and targeting. Nature 1998, 392, 5.
11. Duncan, R. The dawning era of polymer therapeutics. Nat. Rev. Drug Discov. 2003, 2, 347.
12. Schmeltzer, R. C.; Schmalenberg, K. E.; Uhrich, K E. Synthesis and Cytotoxicity of Salicylate-Based Poly(anhydride esters) Biomacromolecules 2005, 6, 359.
13. Erdmann, L.; Macedo, B.; Uhrich, K. E. Degradable poly(anhydride ester) implants: effects of localized salicylic acid release on bone. Biomaterials 2000, 21, 2507.
14. Uhrich, K E.; Giroux, K. J. PCT Int. Appl. WO 2004045549, 2004.
15. Regelson, W.; Kuhar S.; Tunis, M.; Fields, J.; Johnson J.; Gluesenkamp, E. Synthetic polyelectrolytes as tumour inhibitors. Nature 1960, 186, 778.
16. Breslow, D. S. Biologically active synthetic polymers. Pure Appl. Chem. 1976, 46, 103.
17. Johnson, L. R. Physiology of Gastrointestinal Tract; Raven Press: New York, 1994.
18. Braun, E. J. Regulation of renal and lower gastrointestinal function: role in fluid and electrolyte balance. Comp. Biochem. Physiol., A 2003, 136A, 499.
19. Hsu, C. Are we mismanaging calcium and phosphate metabolism in renal failure? Am. J. Kidney Dis. 1997, 29, 641.
20. Ribeiro, S.; Ramos, A.; Brandao, A. Cardiac valve calcification in hemodialysis patients: role of calcium-phosphate metabolism. Nephrol., Dial., Transplant. 1998, 13, 2037.
21. Coburn, J. W.; Norris, K C.; Sherrard, D. J.; Bia, M.; Llach, F.; Alfrey, A. C.; Slatopolsky, E. Toxic effects of aluminum in end-stage renal disease: discussion of a case. Am. J. Kidney Dis. 1988, 12, 171.
22. Block, G.; Hulbert-Shearon, T.; Levin, N. Association of serum phosphorous and calciumxphosphate product with mortality risk in chronic hemodialysis patients: a national study. Am. J. Kidney Dis. 1998, 31, 607.
23. Schmidtchen, F. P.; Berger, M. Artificial Organic Host Molecules for Anions. Chem. Rev. 1997, 97, 1609.
24. Hosseini, M. W.; Lehn, J. M. Binding of AMP, ADP, and ATP nucleotides by polyammonium macrocycles. Helv. Chim. Acta 1987, 70, 1312.
25. Tobey, S. L.; Anslyn, E. V. CSV symmetric receptors show high selectivity and high affinity for phosphate. J. Am. Chem. Soc. 2003, 125, 4026.
26. Dietrich, B.; Fyles, D. L.; Fyles, T. M.; Lehn, J. M. Anion coordination chemistry: polyguanidmium salts as anion complexons. Helv. Chim. Acta 1979, 62, 2763.
27. Hider, R. C.; Canas-Rodriguez, A. Guanidino group-containing polymers for decreasing blood phosphate levels. U.S. Patent 5,698,190, 1997.
28. Hider, R. C.; Canas-Rodriguez, A. Method of medical treatment using guanidine containing polymers. U.S. Patent 6,-132,706, 2000.
29. Holmes-Farley, S. R.; Mandeville, W. H.; Whitesides, G. M. Phosphate-binding polymers for oral administration. U.S. Patent 5,496,545, 1996.
30. Holmes-Farley, S. R.; Mandeville, W. H.; Whitesides, G. M. Phosphate-binding polymers for oral administration. U.S. Patent 5,667,775, 1997.
31. Holmes-Farley, S. R.; Mandeville, W. H.; Ward, J.; Miller, K. L. Design and characterization of sevelamer hydrochloride: a novel phosphate-binding pharmaceutical. J. Macromol. Sci., Pure Appl. Chem. 1999, A36, 1085.
32. Mandeville, W. H.; Holmes-Farley, S. R. Poly(diallyl-amine)-based phosphate binder. U.S. Patent 6,726,905, 2004.
33. Chertow, G. M.; Burke, S. K.; Lazarus, J. M.; Stenzel, K. H.; Womboldt, D.; Goldberg, D.; Bonventre, J. V.; Slatopolsky, E. Poly(allylamine hydrochloride): a noncalcemic phosphate binder for the treatment of hyperphosphatemia in chronic renal failure. Am. J. Kidney Dis. 1997, 29, 66.
34. Slatopolsky, E.; Burke, S. K.; Dillon, M. A. Renagel, a nonabsorbed calcium- and aluminum-free phosphate binder, lowers serum phosphorous and parathyroid hormone. Kidney Int. 1999, 56, 299.
35. Amin, N. The impact of improved phosphorous control: use of sevelamer hydrochloride in patients with chronic renal failure. Nephrol., Dial., Transplant. 2002, 17, 340.
36. Bleyer, A. J.; Burke, S. K.; Dillon, M. A. A comparison of the calcium-free phosphate binder sevelamer hydrochloride with calcium acetate in the treatment of hyperphosphatemia in hemodialysis patients. Am. J. Kidney Dis. 1999, 33, 6694.
37. Crichton, R. R. Inorganic Biochemistry of Iron Metabolism; Ellis Harwood: New York, 1991.
38. Halliwell, B.; Gutteridge, J. M. C. Free radicals in biology and medicine, 2nd ed.; Clarendon Press: Oxford, UK, 1989.
39. Weatherall, D. J.; Clegg, J. B. The Thalassaemia Syndromes, 3rd ed.; Blackwell Scientific Press: Oxford, UK, 1981.
40. Cuthbert, J. A. Iron, HFE, and hemochromatosis update. J. Invest. Med. 1997, 45, 518.
41. Liu, Z. D.; Hider, R. C. Design of clinically useful iron(III) selective chelators. Med. Res. Rev. 2002, 26, 64.
42. Porter, J. B.; Jawson, M. C.; Huehns, E. R.; East, C. A.; Hazell, J. W. P. Desferrioxamine toxicity: evaluation of risk factors in thalassaemic patients and guidelines for safe dosage. Br. J. Haematol. 1989, 73, 403.
43. Badman, D. G.; Bergeron, R. J.; Brittenham, G. M. Iron chelators: new development strategies; The Saratoga group: Florida, 2000.
44. Miller, M. J. Synthesis and therapeutic potential of hydroxamic acid based siderophores and analogues. Chem. Rev. 1989, 89, 1563.
45. Mandeville, W. H.; Holmes-Farley, S. R. Iron-binding polymers for oral administration. U.S. Patent 5,487,888, 1994.
46. Polomoscanik, S. C.; Cannon, C. P.; Neenan, T. X.; Holmes-Farley, S. R. Mandeville, W. H.; Dhal, P. K. Hydroxamic acid containing hydrogels for nonabsorbed iron chelation therapy: synthesis, characterization and biological evaluation. Biomacromolecules, submitted.
47. Grundy, S. M. The role of cholesterol management in coronary disease risk reduction in elderly patients. Endocrinol. Metab. Clin. North Am. 1998, 27, 655.
48. Denke, M. A.; Sempos, C. T.; Grundy, S. M. Excess body weight. An underrecognized contributor to high blood cholesterol levels in white American men, Arch. Int. Med. 1993, 153, 1093.
49. Executive summary of the third report of the "National Cholesterol Education (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults". J. Am. Med. Assoc. 2001, 285, 2486.
50. Sempos, C. T.; et al. Prevalence of high blood cholesterol among US adults. J. Am. Med. Assoc. 1993, 269, 3009.
51. Ziajka, P. E.; Wehmeier, T. Peripheral neuropathy and lipid lowering therapy. Scand. Med. J. 1998, 91, 667.
52. Rader, D. J. A new feature on cholesterol-lowering therapies. Nat. Med. 2001, 7, 1282.
53. Brown, M. S.; Goldstein, J. L. A proteolytic pathway that controls the cholesterol content of membranes, cells, and blood. Proc. Natl. Acad. Sci. U.S.A. 1999, 96, 11041.
54. Grundy, S. M. In Phramacological Control of Hyperlipdaemia; Fears, R., Ed.; Prous Science Publishers, S. A.: Barcelona, Spain, 1986; p 3.
55. Stedronsky, E. R. Interaction of bile acids and cholesterol with nonsystemic agents having hypocholesterolemic properties. Biochim. Biophys. Acta 1994, 1210, 255.
56. Mandeville, W. H.; Goldberg, D. I. The sequestration of bile acids. A nonabsorbed method for cholesterol reduction. Curr. Pharm. Des. 1997, 3, 15.
57. Zarras, P.; Vogl, O. Polycationic salts as bile acid sequestering agents. Prog. Polym. Sci. 1999, 24, 485.
58. Grundy, S. Bile acid sequestrants: do they have a future. In Drugs Affecting Lipid Metabolism; Paoletti, R., Ed.; Springer-Verlag; Berlin, 1987; p 34.
59. Mandeville, W. H.; Arbeeny, C. Bile acid sequestrants: their use in combination with other lipid-lowering agents. Idrugs 1999, 2, 237.
60. Mandeville, W. H.; Braunlin, W.; Dhal, P.; Guo, A.; Huval, C.; Holmes-Farley, S. R.; et al. Three generation of bile acid sequestrants. Mater. Res. Soc. Symp. Proc. 1999, 550, 3.
61. Holmes-Farley, S. R.; Mandeville, W. H.; Burke, S. K.; Goldberg, D. I. Method for treating hypercholesterolemia with polyallylamine polymers. U.S. Patent 6,423,754, 2002.
62. Holmes-Farley, S. R.; Dhal, P. K.; Petersen, J. S. Poly(diallylamine)- based bile acid sequestrants. U.S. Patent 6,203,-785, 1998.
63. Huval, C. C.; Holmes-Farley, S. R.; Mandeville, W. H.; Sacchiero, R.; Dhal, P. K. Syntheses of hydrophobically modified cationic hydrogels by copolymerization of alkyl substituted diallylamine monomers and their use as bile acid sequestrants. Eur. Polym. J. 2004, 40, 693.
64. Zhang, L.; Janout, V.; Renner, J. L.; Uragami, M.; Regen, S. L. Enhancing the "stickiness" of bile acids to cross-linked polymers: a bioconjugate approach to the design of bile acid sequestrants. Bioconjugate Chem. 2000, 11, 397.
65. Huval, C. C.; Bailey, M. J.; Holmes-Farley, S. R.; Mandeville, W. H.; Sacchiero, R.; Dhal, P. K. Amine functionalized polyethers as bile acid sequestrants: synthesis and biological evaluation. J. Macromol. Sci., Pure Appl. Chem. 2001, A38, 1559.
66. Cameron, N. S.; Eisenberg, A.; Brown, G. R. Amphiphilic block copolymers as bile acid sequestrants: synthesis of polystyreneo-poly(N,N,N- trimethylammoniumethylene acrylamide chloride). Biomacromolecules 2002, 3, 116.
67. Gaudilliere, B.; Bernardellli, P; Berna, P. To market, to market-2000. Ann. Rep. Med. Chem. 2001, 36, 293.
68. Bays, H.; Dujovne. Colesevelam HCl: a nonsystemic lipid-altering drug. C. Expert Opin. Pharmacother. 2003, 4, 779.
69. Choi, S.-K. Synthetic Multivalent Molecules: Concepts and Biomedical Applications; Wiley-Interscience: New York, 2004.
70. Mammen, M.; Choi, S. K.; Whitesides, G. M. Polyvalent interactions in biological systems: implications for design and use of multivalent ligands and inhibitors. Angew. Chem., Int. Ed. 1998, 37, 2754.
71. Borman, S. Multivalency: Strength in numbers. Chem. Eng. News 2000, 78, 48.
72. Mammen, M.; Dahmann, G.; Whitesides, G. M. Effective inhibitors of hemagglutination by influenza virus synthesized from polymers having active ester groups: insight into mechanism of inhibition. J. Med. Chem. 1995, 38, 4179.
73. Henderson, B.; Wilson, M.; Wren, B. Are bacterial exotoxins cytokine network regulators? Trends Microbiol. 1997, 5, 454.
74. Rauchhaus, M.; Coats, A. J. S.; Anker, S. D. The endotoxin-lipoprotein hypothesis. Lancet 2000, 356, 930.
75. Beutler, B.; Poltorak, A. Sepsis and evolution of the innate immune response. Crit. Care Med. 2001, 29, S2.
76. Sibbald, W. J.; Vincent, J. L. Clinical Trials for Treatment of Sepsis; Springer: Berlin, Germany, 1995.
77. Dixon, T. C.; Meselson, M.; Guillemin, J.; Hanna, P. C. Anthrax. New Engl. J. Med. 1999, 341, 815.
78. Bartlett, J. G. Clostridium difficile: history of its role as an enteric pathogen and the current state of knowledge about the organism. Clin. Infect. Dis. 1994, 18, S265.
79. Kelly, C. P.; LaMont, T. C. difficile infection. Annu. Rev. Med. 1998, 19, 375.
80. Spencer, R. C. Clinical impact and associated costs of Clostridium difficile associated disease. J. Antimicrob. Chemother. 1998, 41, 5.
81. Taylon, N. S.; Bartlett, J. G. Binding of Clostridium difficile cytoxin and vancomycin by anion-exchange resins. J. Infect. Dis. 1980, 141, 92.
82. Bacon-Kurtz, C.; Fitzpartick, R. Anionic polymers as toxin binders and antibacterial agents. U.S. Patent 6,290,946, 2001.
83. Fitzpatrick, R.; Huval, C. C.; Bacon-Kurtz, C. I.; Mandeville, W. H.; Neenan, T. X. Cationic polymers as toxin-binding agents. U.S. Patent 62,909,47, 2001.
84. Braunlin, W.; Xu, Q.; Hook, P.; Fitzpatrick, R.; Klinger, J. D.; Burrier, R.; Kurtz, C. B. Toxin binding of tolevamer, a polyanionic drug that protects against antibiotic-associated diarrhea. Biophys. J. 2004, 87, 534.
85. Kurtz, C. B.; Cannon, E. P.; Brezzani, A.; Pitruzzello, M.; Dinardo, C.; Rinard, E.; Acheson, D. W. K.; Fitzpatrick, R.; Kelly, P.; Shackett, K.; Papoulis, A. T.; Goddard, P. J.; Barker, R. H., Jr.; Palace, G. P.; Klinger, J. D. GT160-246, a toxin binding polymer for treatment of Clostridium difficile colitis. J. Antimicrob. Chemother, 2001, 45, 2340.
86. Nilsson, U. J.; Heerze, L. D.; Liu, Y.-C.; Armstrong, G. D.; Palcic, M. M.; Hindsgaul, O. Immobilization of reducing sugars as toxin binding agents. Bioconjugate Chem. 1997, 8, 466.
87. Heerze, L. D.; Armstrong, G. D. Treatment of C. difficile toxin B associated conditions. U.S. Patent 63,589,30, 2002.
88. Kotra, L. P.; Golemi, D.; Vakulenko, S.; Mobashery, S. Bacteria fight back. Chem. Ind. 2000, 10, 341.
89. Pearson, H. "Superbug" hurdles key drug barrier. Nature 2002, 418, 469.
90. Walsh, C. Molecular mechanisms that confer antibacterial drug resistance. Nature 2000, 406, 775.
91. Reid, G.; Sobel, J. D. Bacterial adherence in the pathogenesis of urinary tract infection: a review. Rev. Infect. Dis. 1987, 9, 470.
92. Mandeville, W. H.; Garigapati, V. R. Acid-functionalized saccharide polymers as polyvalent anti-infectives. U.S. Patent 5,700,458, 1997.
93. Maloy, W. L.; Kari, U. P. Structure-activity studies on magainins and other host defense peptides. Biopolymers 1995, 37, 105.
94. Mandeville, W. H.; Neenan, T. X.; Holmes-Farley, S. R. Cationic polymers as anti-infective agents. U.S. Patent 6,034,129, 1998.
95. Matukaitis, J. M. The emerging recognition of cryptosporidium as a health hazard. J. Community Health Nursing 1997, 14, 135.
96. Rodgers, G. P.; Noguchi, C. T.; Schechter, A. N. Sickle cell anemia. Sci. Am. Sci. Med. 1994, 1, 48.
97. Persons, D. A. Update on gene therapy for hemoglobin disorders. Curr. Opin. Mol. Ther. 2003, 5, 508.
98. Smith, C. M.; Hebbel, R. P.; Tukey, D. P.; Clawson, C. C.; White, J. G.; Vercellotti, G. M. Pluronic F-68 reduces the endothelial adherence and improves the rheology of liganded sickle erythrocytes. Blood 1987, 69, 1631.
99. Patrickios, C. S.; Georgiou, T. K. Covalent amphiphilic polymer networks. Curr. Opin. Colloid Interface Sci. 2003, 8, 76.
100. Schmolka, I. R. A review of block polymer surfactants. J. Am. Oil Chem. Soc. 1977, 54, 110.
101. Gibbs, W. J.; Hagemann, T. M. Purified poloxamer 188 for sickle cell vaso-occlusive crisis. Ann. Pharmacother. 2004, 38, 320.
102. Orringer, E. P.; et al. Purified Poloxamer 188 for treatment of acute vaso-occlusive crisis of sickle cell disease: A randomized controlled trial. J. Am. Med. Assoc. 2001, 286, 2099.